The Agenus (AGEN) saga just keeps getting more interesting with the twists and turns reaching back through time. My first article on the company back in August chronicles its history twenty years back, with special focus on Prophage, then called Oncophage, the company's heat shock protein [HSP] cancer vaccine platform. As a quick review, Prophage makes use of HSP's as an "antigen mold," so to speak, which allows immune cells called dendritic cells to pick up the antigens of a tumor from those HSP proteins which fold themselves around the tumor antigens.
Back in 2002, Agenus initiated a high profile phase 3 study of Prophage for melanoma. It failed miserably, not because Prophage failed to meet any...
Only subscribers can access this article, which is part of the PRO research library covering 3,582 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: